Breakthrough Medicine

About Breakthrough Medicine

Sujana Biotech is developing novel therapeutics for inflammatory and vascular diseases
Binding of the leukocyte-expressed integrin macrophage-1 antigen (Mac-1) to platelet-expressed glycoprotein Ibα (GPIbα) is a key event mediating inflammation-associated transmigration of leukocytes out of the vasculature. The Scientific Founders, Dan Simon, Ed Plow, and Yunmei Wang have shown that the strong interaction between Mac-1 and GPIbα is critically dependent on a short segment of Mac-1 (termed the “M2” region). They have also demonstrated that M2 is not critical for the binding of Mac-1 to other important ligands such as fibrinogen and that selective inhibition of the GPIbα interaction through M2-directed strategies is possible without affecting Mac-1 interactions with other binding partners. These observations suggest that novel therapeutics targeting M2 may inhibit a number of pathological inflammatory conditions without compromising other innate immune or hemostatic functions.
Preclinical studies in a variety of animal models indicate that leukocyte engagement of platelet GPIbα via Mac-1 is critical for the pathophysiological response to mechanical vascular injury and also implicate the GPIbα-Mac-1 interaction in the development and progression of thrombosis, vasculitis, glomerulonephritis, and multiple sclerosis.

Collectively, the data advance the hypothesis that inflammation is broadly platelet-dependent and that therapeutic strategies directed against M2 may offer an innovative, effective approach to diverse inflammatory diseases.

Write Your Reviews

Writing great reviews may help others discover the places that are just apt for them. Here are a few tips to write a good review:

3 Star

Be the First One To Review This Listing!!!

Company Info

Year Founded 2015
Number of Employees 50 - 99
Minimal Budget $10,000 - $25,000

Our Location

Tower East, Shaker Heights , Ohio 44122 , United States
View Map